See the DrugPatentWatch profile for Ketamine
Ketamine is available as both a brand-name drug and a generic medication. The brand name for intravenous ketamine is Ketalar, while the nasal spray formulation is known as Spravato [1]. Generic versions of ketamine are also available, which can offer a more affordable treatment option [2].
When does ketamine patent exclusivity end?
Patent exclusivity for ketamine products can vary. For Spravato (esketamine), the active ingredient is esketamine, which is closely related to ketamine. The patent landscape for Spravato and its active ingredient is complex and involves multiple patents covering the compound, its uses, and methods of administration. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide detailed timelines for patent expiry and any associated exclusivities [3].
What are the different forms of ketamine treatment?
Ketamine is administered in several forms, each with specific uses and approval statuses.
* Intravenous (IV) Ketamine: This is the established form, often used off-label for conditions like chronic pain and depression. While the original patents on ketamine itself have long expired, allowing for generic availability, specific formulations or administration methods might have their own patent protections [1][2].
* Esketamine Nasal Spray (Spravato): This is an FDA-approved medication specifically for treatment-resistant depression and depressive symptoms in adults with major depressive disorder, with suicidal thoughts or actions. Its development and approval by Janssen Pharmaceuticals have led to specific patent protections for the esketamine nasal spray and its therapeutic uses [1].
How does Spravato (esketamine) differ from generic ketamine?
The primary difference lies in their regulatory status and approved indications. Spravato, containing esketamine, is specifically FDA-approved for certain mood disorders [1]. Generic ketamine, while widely used for anesthesia and increasingly explored for off-label psychiatric uses, does not have these specific FDA approvals for depression or related conditions. Spravato's approval came with a Risk Evaluation and Mitigation Strategy (REMS) due to potential side effects like sedation and dissociation [4].
Can generic ketamine be used for depression?
While Spravato (esketamine) is approved for treatment-resistant depression, clinicians may prescribe generic ketamine off-label for depressive disorders. This practice is based on emerging clinical research and the drug's known effects on brain pathways associated with mood. However, off-label use means it is not FDA-approved for this specific indication, and insurance coverage may differ compared to an approved drug like Spravato [1][5].
What are the potential risks and side effects of ketamine treatments?
Both intravenous ketamine and esketamine nasal spray carry risks. Common side effects include sedation, dizziness, dissociation (feeling detached from oneself or reality), nausea, and elevated blood pressure. More serious concerns can include the potential for abuse, bladder problems with long-term or high-dose use, and temporary perceptual changes. Due to these risks, Spravato is administered under medical supervision, and patients are monitored for at least two hours after administration [4][5].
What is the cost of ketamine and Spravato?
The cost can vary significantly. Generic ketamine, particularly for intravenous administration, is generally less expensive than brand-name Spravato. Spravato's cost reflects its research, development, and FDA approval process. Patient assistance programs and insurance coverage can influence out-of-pocket expenses for both treatments [2][4].
Who develops and markets ketamine and Spravato?
Ketamine, as an older anesthetic drug, has its original patents expired, allowing multiple pharmaceutical companies to manufacture generic versions. Spravato (esketamine) was developed and is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
---
Sources
[1] U.S. Food & Drug Administration. (n.d.). Spravato (esketamine) nasal spray. Retrieved from [FDA Website Link Placeholder]
[2] DrugPatentWatch.com. (n.d.). Ketamine Drug Information. Retrieved from [DrugPatentWatch.com Website Link Placeholder]
[3] DrugPatentWatch.com. (n.d.). Spravato (esketamine) Drug Information. Retrieved from [DrugPatentWatch.com Website Link Placeholder]
[4] Janssen Pharmaceuticals. (n.d.). Spravato (esketamine) prescribing information. Retrieved from [Manufacturer Website Link Placeholder]
[5] National Institute of Mental Health. (n.d.). Ketamine for Depression. Retrieved from [NIMH Website Link Placeholder]